Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12511780 | 0.86 | SIGMAR1 (0.61) | SIGMAR1MEN1KMT2AMCHR1 | |
| SCHEMBL2210339 | 0.85 | ADIPOR2 (0.63) | SIGMAR1MEN1KMT2AMCHR1 | |
| SCHEMBL2215875 | 0.85 | SIGMAR1 (0.60) | SIGMAR1MEN1KMT2AMCHR1 | |
| SCHEMBL4034602 | 0.85 | SIGMAR1 (0.83) | SIGMAR1MEN1KMT2AMCHR1 | |
| SCHEMBL4034737 | 0.84 | SIGMAR1 (0.81) | SIGMAR1MEN1KMT2A | |
| SCHEMBL2211108 | 0.83 | UTS2R (0.62) | SIGMAR1MEN1KMT2AMCHR1 | |
| SCHEMBL6105485 | 0.83 | MEN1 (0.56) | SIGMAR1MEN1KMT2AMCHR1 | |
| SCHEMBL2213070 | 0.82 | UTS2R (0.64) | SIGMAR1MEN1KMT2AMCHR1 | |
| SCHEMBL2211685 | 0.82 | SIGMAR1 (0.57) | SIGMAR1MEN1KMT2AMCHR1 | |
| SCHEMBL7487718 | 0.82 | SIGMAR1 (0.74) | SIGMAR1MEN1KMT2AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | SIGMAR1 2000/4885MEN1 3525/4885KMT2A 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.